There is increasing evidence that TLR4 is a potential therapeutic target for neuroinflammation after hypoxic–ischemic encephalopathy (HIE), and the inhibition of TLR4 has been shown to have a neuroprotective effect on brain damage (Tang et al., 2019). The gene discussed is TLR4; the disease is perinatal asphyxia.